Biotop-report 2011
Yüklə 0,8 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- Biotech Networks
- Prof. Dr. Christine Lang
- Ralf Christoffers
32 B i o T O P i c s 4 2 _ B i o T O P R e p o r t 2 0 1 1 Netzwerk Glykobiotechnologie Berlin-Brandenburg BIOTECH CAMPUS POTSDAM GmbH Biotech Networks BioHyTec Network for Biohybrid Technologies BioResponse Center for Molecular Diagnostics and Bioanalytics (ZMDB) DiagnostikNet-BB GABI – Genome Analysis in the Plant Biological System NetDDD Network for Drug Discovery & Development Berlin-Brandenburg Network Glycobiotechology Berlin-Brandenburg Nutrigenomics Network Berlin-Brandenburg Regenerative Medicines Initiative Berlin-Brandenburg RiNA Network for RNA Technologies Ultrastructure Network
Berlin-Brandenburg Center for Regenerative Therapies Berlin Institute of Technology Brandenburg University of Technology Charité – Universitätsmedizin Berlin Fraunhofer Institute for Applied Polymer Research Fraunhofer Institute for Biomedical Engineering (IBMT) Freie Universität Berlin German Heart Instiute Berlin German Institute of Human Nutrition (DIfE) German Rheumatism Research Center (DRFZ) Humboldt-Universität zu Berlin Institute of Polymer Research of the GKSS Research Centre Lausitz University of Applied Sciences Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) Leibniz-Institut für Molekulare Pharmakologie (FMP) Leibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V. Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch Max-Planck-Institute for Colloids and Interfaces Max Planck Institute for Infection Biology Max Planck Institute for Molecular Genetics Max Planck Institute of Molecular Plant Physiology Robert Koch Institute University of Applied Sciences Berlin University of Applied Sciences Wildau University of Potsdam P Bioparks P
Scientific Institutions P Companies P
33 B i o T O P i c s 4 2 _ B i o T O P R e p o r t 2 0 1 1 FH I I 34 B i o T O P i c s 4 2 _ B i o T O P R e p o r t 2 0 1 1 Further deals include the global license agreement closed by the company Organobalance with Lonza for the development and marketing of the unique probiotic agent lactobacillus anti-H- pylori. This probiotic strain is effective against helicobacter pylori. Studies have shown that H-pylori often contribute to the genera- tion of gastric ulcers and gastritis. In April 2010, the biophar- maceutical company Co.don which specialises in cartilage treat- ments, closed an exclusive agreement with the Swiss company Novomedics to launch the cell-based drug chondrosphere ® on
the Swiss market. The option to treat damage to cartilage in the knee, hip, elbow and shoulder joints with the three-dimensional autologous cell transplant chondrosphere ® provides doctors and patients with new possibilities for gentle and personalised ther- apy.
Two major transactions were closed in the acquisition sector in 2010. The Berlin service provider for genome research imagenes was taken over to 100 per cent by the British Source BioScience Group. The transaction has created a modern medicine and bio- science service provider unique in Europe offering more than 20 million clones, 90,000 antibodies and a comprehensive range of functional and structural genome analysis services. The com- pany Cyano Biofuels which focuses on biotechnological applica- tions of cyanobacteria and specifically on their development and optimisation for the production of environment-friendly biofu- els and raw chemicals, was fully taken over by the US company Algenol Biofuels. Further progress was also made in the area of product develop- ment. In the drug development segment, companies like NOXXON, Revotar, MOLOGEN and Glycotope launched or already completed their first clinical trials. MOLOGEN initiated Phase II/III approval studies for its colon cancer drug MGN1703. The company is pur- suing a promising concept for cancer therapy using the immu- nomodulator and TLR9 agonist dSLIM, which is based on broad activation of the immune system. Revotar AG completed a major Phase IIa clinical study for COPD (Chronic Obstructive Pulmonary Disease) with positive topline results. Today, around five million people worldwide die of COPD every year, and the numbers are rising.
Overall, the regional industry is developing very well. This positive trend is reflected in the consistent pursuit of development goals by companies in the capital-intensive segments, rising employ- ment, increasing internationalisation and, last but not least, the fact that there have been no insolvencies of importance.
CEO · ORGANOBALANCE GmbH Bacteria in the Service of Health » In the ten years since ORGANOBALANCE was founded we have managed to acquire a strong position in white biotechnology based on our expertise in the development of innovative probiotic strains. In 2010, we took another step forward with the founding of ORGANOBALANCE Medical AG. We are con- vinced that microorganisms can also be developed as effective, safe and well- tolerated products for prevention and therapy in human medicine. Our first major project aims to control the stomach bacterium helicobacter pylori. In the Lonza Group, we have found a strong partner for product development and global marketing of an application in food. EU Commission President José-Manuel Barroso and Minister Ralf Christoffers at the award ceremony honouring Brandenburg as one of three European “Regions of Excellence”
Minister of Economics and European Affairs of Brandenburg Brandenburg Receives European Region of Excellence Award » The European Union has awarded the distinction “Region of Excellence” to the state of Brandenburg. I am very pleased by this great honour. After the Committee of the Regions nominated Brandenburg as a ‘European Entre- preneurial Region 2011’, we received further confirmation that we are right on course in developing Brandenburg as a business location with the award of the European Region of Excellence title. The EU has thereby certified that our state offers companies an environment that stands out in Europe. Yüklə 0,8 Mb. Dostları ilə paylaş:
|